AIP Arteris, Inc. Insider Trading

CEO K Charles Janac sold 136,655 shares ($4.9M) across 6 transactions on 2026-07-06 under 10b5-1 plan

K Charles Janac, President and CEO, executed 6 separate sales totaling 136,655 shares for $4,892,592.32 on 2026-07-06, reducing holdings from 8.57M to 8.43M shares (-1.6%). The transaction was part of a pre-arranged 10b5-1 trading plan adopted on 2025-12-12, making it scheduled rather than discretionary. The company's recent fundamentals show revenue of $22,936,000 (latest quarter) with net income of $-7,959,000 and full-year unprofitability, while the stock is -31.4% from its 52-week high of $50.26. The sale prices ranged from $35.06 to $37.12, while current price sits at $34.46. Investors should note this is a scheduled liquidation under a formalized plan, not a sudden discretionary decision by the CEO, and the scale ($4.9M divested) represents material CEO capital movement despite the company's current unprofitable state.

10% Owner Bayview Legacy sells 125,976 shares at blended $35.79 via scheduled 10b5-1 plan; stock -31.4% from peak.

Bayview Legacy, LLC, a 10% owner, executed three separate sales totaling 125,976 shares (126.0K shares) for $4,509,184.86 ($4.5M) on 2026-07-06 at an average price of $35.79, reducing holdings by 1.5% to 8,429,071 shares. The transaction is part of a pre-arranged 10b5-1 trading plan, meaning it is scheduled rather than discretionary. At the current price of $34.46, the stock is -31.4% from its 52-week high of $50.26 and has declined -2.3% over the past 30 days despite a +76.2% gain over 90 days. Arteris remains unprofitable (full-year net income was negative) despite posting 22.3% annual revenue growth to $22.9M, with the latest quarter showing a $-8.0M net loss. The insider's prior trade outcomes at this ticker are mixed, with three recent sales on 2026-06-08 and 2026-05-08 not yet showing measurable longer-term results, while a December 2025 sale resulted in a -1.7% 30-day return and -18.0% 90-day return.

Arteris CEO Charles Janac sells 192,686 shares for $6,998,653.89 via pre-arranged 10b5-1 plan on 2026-07-02

K Charles Janac executed 8 separate sales totaling 192,686 shares for $6,998,653.89 on 2026-07-02 as part of a pre-arranged 10b5-1 trading plan. The blended average price of $36.32 occurs in a context where the stock currently trades at $34.82, down 30.7% from its 52-week high of $50.26 yet up 92.2% over 90 days. Post-transaction, Janac retains 8,555,047 shares, a 2.2% reduction from pre-transaction holdings. At the company level, Arteris reports quarterly revenue of $22,936,000.00 with a net loss of $7,959,000.00 and was unprofitable over its most recent full fiscal year, though annual revenue growth reached 22.3%. The scheduled nature of this transaction (per 10b5-1 plan) removes discretionary timing as a signal, but the multi-tranche execution across a range of prices ($34.77–$43.24) reflects typical programmatic liquidation mechanics.

Bayview Legacy sells 192,686 shares for $6,998,653.89 under 10b5-1 plan; still holds 8,555,047 shares post-transaction.

Bayview Legacy, LLC executed 8 separate sales totaling 192,686 shares for $6,998,653.89 on 2026-07-02 under a pre-arranged 10b5-1 trading plan, reducing its stake from 8,747,733 to 8,555,047 shares (a -2.2% reduction). The blended average price of $36.32 compares to the current price of $34.82, placing the stock 30.7% below its 52-week high of $50.26. At the same ticker, the insider's 5 prior trades show mixed outcomes: the most recent measurable result from 2025-12-08 posted a 90-day return of -18.0%. The company reported net income of $-7,959,000.00 over its latest full fiscal year despite annual revenue growth of +22.3%, indicating growth has not yet translated to profitability.

Bayview Legacy LLC sells 181,338 shares at $45.46 avg for $8.2M; stock now at $35.06, down -30.2% from 52-week high

Bayview Legacy, LLC completed 4 separate sales totaling 181,338 shares for $8,243,334.21 on 2026-07-01 under a pre-arranged 10b5-1 trading plan, reducing its stake from 8,929,071 to 8,747,733 shares (-2.0%). The sales occurred at prices ranging from $44.06 to $47.08, with a blended average of $45.46, but the stock has since declined to $35.06, now trading -30.2% below its 52-week high and -7.6% over the past 30 days. Bayview's cross-ticker track record shows 7 prior sells with an average 90-day return of -2.7%, while at AIP specifically, the most recent measurable same-ticker trade (2025-12-08) posted a 90-day return of -18.0%, suggesting this insider has experienced volatile post-sale performance at this name. The company itself faces fundamental headwinds: it reported net income of -$7,959,000 for the latest quarter while remaining unprofitable over its most recent full fiscal year, despite annual revenue growth of +22.3%.

CEO Charles Janac sells 181,338 shares for $8,243,334.21 at AIP; stock down 30.2% from 52-week high, per 10b5-1 plan.

K Charles Janac, President and CEO of Arteris, Inc., executed 4 separate sales totaling 181,338 shares for $8,243,334.21 on 2026-07-01 under a pre-arranged 10b5-1 trading plan, reducing his holdings by 2.0% to 8,747,733 shares. The stock is currently trading at $35.06, down 30.2% from its 52-week high of $50.26 and down 7.6% over the prior 30 days, despite a 92.6% gain over 90 days. At the same ticker, Janac's prior measurable trade on 2026-03-26 showed a 30-day return of +45.6% and 90-day return of +123.6%, but the current transaction's scheduled nature under the 10b5-1 plan means it was not discretionary. The company reported revenue of $22,936,000.00 and net income of $-7,959,000.00 in its latest quarter, with an annual revenue growth rate of +22.3%, but full-year results remain unprofitable.

Director Saiyed Atiq Raza sold 70,000 shares ($3.2M) via 4 sales on 2026-07-01 under 10b5-1 plan

Director Saiyed Atiq Raza executed 4 separate sales totaling 70,000 shares for $3,176,979.55 on 2026-07-01, reducing his holdings by exactly 50.0% from 140,000 to 70,000 shares. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-11-07, meaning it was scheduled rather than discretionary. At the time of sale, the blended average price was $45.39; the current stock price is now $35.06, representing a -30.2% decline from the 52-week high of $50.26. Raza's prior sales at Arteris show consistent positive returns measured 30 days post-transaction (ranging from +20.2% to +57.7% across his last 5 trades at this ticker), though the company itself is unprofitable with net income of $-7,959,000.00 in the latest quarter and a full-year net income that was negative.

COO Laurent Moll sells 39,541 shares of AIP at $43.15; 90d track record 100% well-timed at ticker level

Laurent R Moll, Chief Operating Officer of Arteris Inc., sold 39,541 shares (39.5K shares) at $43.15 on 2026-06-16, reducing holdings from 266,837 to 227,296 shares (-14.8%). The sale occurred near the 52-week high of $44.94 and notably follows a strong 90-day rally of +164.0% and 30-day gain of +26.6%. His prior three sales at AIP all resulted in negative 90-day returns (-2.8%, -19.0%, -5.9%), establishing a 100% well-timed pattern at this ticker. Across his cross-ticker track record (3 prior sells at other companies), 100.00% of sales were well-timed, with a 90-day average return of -11.1%. The company posted negative net income of $-7,959,000 ($-8.0M) in the latest quarter despite 22.3% annual revenue growth, creating tension between growth trajectory and current profitability—a context in which an executive sell warrant investor scrutiny into near-term headwinds or cash-flow pressures.

CEO K Charles Janac sold 70,000 shares at blended avg $34.91 via scheduled 10b5-1 plan; post-sale holds 8,929,071 shares.

K Charles Janac, President and CEO of Arteris, Inc., executed 2 separate sales totaling 70,000 shares for $2,443,432.56 on 2026-06-08 pursuant to a pre-arranged 10b5-1 trading plan adopted on 2025-03-05. This is a scheduled transaction, not discretionary. His prior 5 sales at AIP produced 90-day returns of +8.2%, +77.3%, +84.0%, +87.2%, and +140.5%, while his broader cross-ticker track record across 20 prior sells averaged +37.4% over 90 days—indicating his recent sales at this ticker have substantially outperformed his typical historical outcomes. The company posted $22.9M in quarterly revenue with a -$8.0M net loss, generating +22.3% annual revenue growth, yet remains unprofitable on a full-year basis. Current stock price of $33.51 sits -14.0% from the 52-week high of $38.99.

10% owner Bayview Legacy, LLC sells 70,000 shares (70.0K shares) for $2,443,432.56 via 10b5-1 plan at AIP

Bayview Legacy, LLC completed 2 separate sales totaling 70,000 shares for $2,443,432.56 on 2026-06-08 under a pre-arranged 10b5-1 trading plan, reducing holdings from 8,999,071 shares to 8,929,071 shares (-0.8%). The transaction is scheduled, not discretionary. At the same-ticker level, the insider's 5 prior trades at AIP show mixed post-transaction performance (returns ranging from -18.0% to +77.3% over 90 days), indicating no clear pattern of consistent timing accuracy. The company reported negative net income ($-7,959,000.00) in its latest quarter despite revenue of $22,936,000.00 and annual growth of +22.3%, suggesting operational challenges beneath top-line expansion. The 10b5-1 structure removes discretionary intent from this filing; the sale reflects a pre-planned execution rather than a contemporaneous market signal.